Tsubota Laboratory, Inc.

Toshiba Materials Co., Ltd.

Agc Inc.

Keio University

Nagoya Institute of Technology

Rohto Pharmaceutical Co., Ltd.

Jins Holdings Inc.

Restore Vision Inc.

Toshihide Kurihara

Kazuo Tsubota

Hidemasa Torii

Masahiko Yamakawa

Hideki Kandori

Kazuno Negishi

Yusaku Katada

Manabu Nishizawa

Akio Koike

Tetsuya Nakashima

Kensuke Nagai

Hiroyuki Hijiya

Shinichi Ikeda

Yutaka Kuroiwa

Masamichi Tanida

Shunsuke Shioya

Xiaoyan Jiang

Hiromitsu Kunimi

A model that closely resembles human excessive myopia can be prepared by mounting a minus lens () and a protector () to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Mouse myopia-induced model and endoplasmic reticulum stress suppressant for preventing and suppressing myopia

A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.

Light source for myopia prevention article and method of using light source for myopia prevention article

The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.

Agent for restoring visual function or agent for preventing deterioration in visual function

The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

Composition and functional food for preventing myopia

Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.

Nucleic acid construct that encodes chimeric rhodopsin

A wavelength-selective transmissive glass has a light transmittance Tat a wavelength of more than 315 nm and 400 nm or less represented by the formula shown below of 1% or more in terms of a plate thickness of 6 mm and a light transmittance Tat a wavelength of 315 nm or less represented by the formula shown below of 60% or less in terms of a plate thickness of 6 mm. Ais a weighting factor at a wavelength k (nm) for calculating T (light transmittance) defined in ISO-9050:2003, and Tis a transmittance at the wavelength k (nm) in terms of a plate thickness of 6 mm:=(&#x3a3;)/(&#x3a3;)=(&#x3a3;)/(&#x3a3;).

Glass

An optical element has a transmission spectrum characterized in that a local maximum falls within a wavelength region longer than 315 nm but shorter than or equal to 400 nm, a local minimum falls within a wavelength region longer than or equal to 380 nm but shorter than or equal to 500 nm, and the wavelength at the local maximum is shorter than the wavelength at the local minimum.

Optical element

The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.

Myopia treatment device

The purpose of the present invention is to provide a myopia prevention device. A myopia prevention device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia. Further, a myopia prevention device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia.

Growing community of inventors

Tokyo, Japan

Toshihide Kurihara